BACKGROUND: Children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNET) have poor outcomes compared to medulloblastoma patients, despite similar treatments. In an effort to improve overall survival (OS) and event-free survival (EFS) and to decrease radiation exposure, the Head Start (HS) protocols treated children with newly diagnosed sPNET utilizing intensified induction chemotherapy (ICHT) followed by consolidation with myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR). PROCEDURES: Between 1991 and 2002, 43 children with sPNET were prospectively treated on two serial studies (HS I and II). After maximal safe surgical resection, patients on HS I and patients with localized disease on HS II were treated with five cycles of ICHT (vincristine, cisplatin, cyclophosphamide, and etoposide). Patients on HS II with disseminated disease received high-dose methotrexate during ICHT. If the disease remained stable or in response, patients received a single cycle of high-dose myeloablative chemotherapy followed by AuHCR. RESULTS: Five-year EFS and OS were 39% (95%CI: 24%, 53%) and 49 (95%CI: 33%, 62%), respectively. Non-pineal sPNET patients faired significantly better than those patients with pineal sPNETs. Metastasis at diagnosis, age, and extent of resection were not significant prognostic factors. Sixty percent of survivors (12 of 20) are alive without exposure to radiation therapy. CONCLUSIONS: ICHT followed by AuHCR in young patients with newly diagnosed sPNET appears to not only provide an improved EFS and OS for patients who typically have a poor prognosis, but also it successfully permitted deferral and elimination of radiation therapy in a significant proportion of patients. (c) 2007 Wiley-Liss, Inc.
BACKGROUND:Children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNET) have poor outcomes compared to medulloblastomapatients, despite similar treatments. In an effort to improve overall survival (OS) and event-free survival (EFS) and to decrease radiation exposure, the Head Start (HS) protocols treated children with newly diagnosed sPNET utilizing intensified induction chemotherapy (ICHT) followed by consolidation with myeloablative chemotherapy and autologous hematopoietic cell rescue (AuHCR). PROCEDURES: Between 1991 and 2002, 43 children with sPNET were prospectively treated on two serial studies (HS I and II). After maximal safe surgical resection, patients on HS I and patients with localized disease on HS II were treated with five cycles of ICHT (vincristine, cisplatin, cyclophosphamide, and etoposide). Patients on HS II with disseminated disease received high-dose methotrexate during ICHT. If the disease remained stable or in response, patients received a single cycle of high-dose myeloablative chemotherapy followed by AuHCR. RESULTS: Five-year EFS and OS were 39% (95%CI: 24%, 53%) and 49 (95%CI: 33%, 62%), respectively. Non-pineal sPNET patients faired significantly better than those patients with pineal sPNETs. Metastasis at diagnosis, age, and extent of resection were not significant prognostic factors. Sixty percent of survivors (12 of 20) are alive without exposure to radiation therapy. CONCLUSIONS: ICHT followed by AuHCR in young patients with newly diagnosed sPNET appears to not only provide an improved EFS and OS for patients who typically have a poor prognosis, but also it successfully permitted deferral and elimination of radiation therapy in a significant proportion of patients. (c) 2007 Wiley-Liss, Inc.
Authors: Eduard H Panosyan; Alan K Ikeda; Vivian Y Chang; Dan R Laks; Charles L Reeb; La Vette Bowles; Joseph L Lasky; Theodore B Moore Journal: J Transplant Date: 2011-04-14
Authors: Carsten Friedrich; André O von Bueren; Katja von Hoff; Nicolas U Gerber; Holger Ottensmeier; Frank Deinlein; Martin Benesch; Robert Kwiecien; Torsten Pietsch; Monika Warmuth-Metz; Andreas Faldum; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski Journal: Neuro Oncol Date: 2012-12-07 Impact factor: 12.300
Authors: C Altshuler; K Haley; G Dhall; L Vasquez; S L Gardner; J Stanek; J L Finlay Journal: Bone Marrow Transplant Date: 2016-03-07 Impact factor: 5.483
Authors: Meihua Li; Kyle F Lee; Yuntao Lu; Ian Clarke; David Shih; Charles Eberhart; V Peter Collins; Tim Van Meter; Daniel Picard; Limei Zhou; Paul C Boutros; Piergiorgio Modena; Muh-Lii Liang; Steve W Scherer; Eric Bouffet; James T Rutka; Scott L Pomeroy; Ching C Lau; Michael D Taylor; Amar Gajjar; Peter B Dirks; Cynthia E Hawkins; Annie Huang Journal: Cancer Cell Date: 2009-12-08 Impact factor: 31.743
Authors: Chantel Cacciotti; Muhammad Ali; Ute Bartels; Jonathan D Wasserman; Erilda Kapllani; Joerg Krueger; Eric Bouffet; Tal Schechter Journal: Childs Nerv Syst Date: 2020-11-18 Impact factor: 1.475